| ID Source | ID |
|---|---|
| PubMed CID | 85955 |
| CHEMBL ID | 155379 |
| SCHEMBL ID | 35551 |
| MeSH ID | M0043227 |
| Synonym |
|---|
| BB 0261748 |
| perhydrodibenzo-18-crown-6 |
| nsc252171 |
| dicyclohexyl-18-crown-6 ether |
| dibenzo[b,4,7,10,13,16]hexaoxacyclooctadecin, eicosahydro- |
| 16069-36-6 |
| dicyclohexo-18-crown-6 |
| dicyclohexyl-18-crown-6 |
| 2,8,15,18,21-hexaoxatricyclo[20.4.0.09,14]hexacosane |
| perhydrodibenzo[18]crown-6 |
| nsc-252171 |
| dicyclohexano-18-crown-6 |
| dibenzo[b,4,7,10,13,16-hexaoxacyclooctadecin, eicosahydro- |
| dch-18-crown-6 |
| einecs 240-216-4 |
| dicyclohexyl 18-crown-6 |
| dibenzo(b,k)-1,4,7,10,13,16-hexaoxacyclooctadecin, eicosahydro- |
| ai3-62377 |
| icosahydrodibenzo(b,k)(1,4,7,10,13,16)hexaoxacyclooctadecin |
| nsc 252171 |
| 2,5,8,15,18,21-hexaoxatricyclo(20.4.0.0(sup 9,14))hexacosane |
| cis-dicyclohexano-18-crown-6 |
| dibenzo(b,k)(1,4,7,10,13,16)hexaoxacyclooctadecin, eicosahydro- |
| ccris 3612 |
| d2-06 |
| 2,5,8,15,18,21-hexaoxatricyclo(20.4.0.09,14)hexacosane |
| 2,3,11,12-dicyclohexano-1,4,7-10,13,16-hexaoxacyclooctadecane |
| brn 1130529 |
| dibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin, eicosahydro- |
| CBDIVE_001514 |
| dicyclohexano-18-crown-6, 98% |
| icosahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecine |
| STK796822 |
| AKOS000519878 |
| CHEMBL155379 |
| inchi=1/c20h36o6/c1-2-6-18-17(5-1)23-13-9-21-11-15-25-19-7-3-4-8-20(19)26-16-12-22-10-14-24-18/h17-20h,1-16h2 |
| bbgkdyhzqosnmu-uhfffaoysa- |
| dicyclohexano-18-crown 6-ether |
| D1668 |
| perhydro-dibenzo-18-crown-6 |
| 2,5,8,15,18,21-hexaoxatricyclo[20.4.0.09.14]hexacosane |
| 2,3,11,12-dicyclohexano-1,4,7,10,13,16-hexaoxacyclooctadecane |
| BBL009691 |
| FT-0624739 |
| AKOS016344456 |
| icosahydrodibenzo[b,k][1,4,7,10,13,16]-hexaoxacyclooctadecine |
| SCHEMBL35551 |
| dicyclohexyl-18 -crown-6 |
| dicyclohexano-l 8-crown-6 |
| crown ether dicyclohexyl-18-crown-6 |
| dicyclohexano-18-crown-6 ether |
| 2,5,8,15,18,21-hexaoxatricyclo[20.4.0.0(9,14)]hexacosane |
| mfcd00005099 |
| J-009746 |
| 2,5,8,15,18,21-hexaoxatricyclo[20.4.0.0?,(1)?]hexacosane |
| VS-02149 |
| D78390 |
| 2,5,8,15,18,21-hexaoxatricyclo[20.4.0.09,14]hexacosane |
| DTXSID30884870 |
| A883190 |
| dicyclohexano-18-crown-6,mixture of isomers |
| CS-W009764 |
| SY010002 |
| 2,5,8,15,18,21-hexaoxatricyclo[20.4.0.0,9,14]hexacosane |
| EN300-18470780 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1614582 | Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 0.2 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%) | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Crown Ethers as Transthyretin Amyloidogenesis Inhibitors. |
| AID280247 | Antiproliferative activity against MiaPaCa2 cells after 72 hrs by MTT assay | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores. |
| AID50775 | In vitro lethal dose of compound against Eimeria tenella in chicken kidney cell cultures | 1983 | Journal of medicinal chemistry, Apr, Volume: 26, Issue:4 | Anticoccidial activity of crown polyethers. |
| AID1614581 | Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 2 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%) | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Crown Ethers as Transthyretin Amyloidogenesis Inhibitors. |
| AID1614591 | Inhibition of ANS binding to TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as increase in BC50 for ANS binding to TTR at 100 mM in presence of 150 mM Na+ by fluorescence-based assay | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Crown Ethers as Transthyretin Amyloidogenesis Inhibitors. |
| AID1614583 | Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 0.6 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%) | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Crown Ethers as Transthyretin Amyloidogenesis Inhibitors. |
| AID1614594 | Inhibition of ANS binding to TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as increase in BC50 for ANS binding to TTR at 10 mM in presence of 150 mM K+ by fluorescence-based assay | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Crown Ethers as Transthyretin Amyloidogenesis Inhibitors. |
| AID280248 | Antiproliferative activity against SW620 cells after 72 hrs by MTT assay | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores. |
| AID280246 | Antiproliferative activity against HeLa cells after 72 hrs by MTT assay | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores. |
| AID1614584 | Inhibition of TTR V30M mutant (unknown origin)-mediated amyloid fibril formation expressed in Escherichia coli assessed as amyloid fibril percentage at 10 mM after 4 days by thioflavin-T-fluorescence based assay (Rvb = 100%) | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Crown Ethers as Transthyretin Amyloidogenesis Inhibitors. |
| AID611986 | Antibacterial activity against Bacillus subtilis after 70 mins | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Could LogP be a principal determinant of biological activity in 18-crown-6 ethers? Synthesis of biologically active adamantane-substituted diaza-crowns. |
| AID1614592 | Inhibition of ANS binding to TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as increase in BC50 for ANS binding to TTR at 10 mM in presence of 150 mM Na+ by fluorescence-based assay | 2019 | Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4 | Crown Ethers as Transthyretin Amyloidogenesis Inhibitors. |
| AID280249 | Antiproliferative activity against MCF7 cells after 72 hrs by MTT assay | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores. |
| AID611984 | Antibacterial activity against Escherichia coli assessed as growth inhibition at 10'-4 M after 105 mins | 2011 | European journal of medicinal chemistry, Aug, Volume: 46, Issue:8 | Could LogP be a principal determinant of biological activity in 18-crown-6 ethers? Synthesis of biologically active adamantane-substituted diaza-crowns. |
| AID280245 | Antiproliferative activity against H460 cells after 72 hrs by MTT assay | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (28.57) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||